South Korea Orphan Drugs Market Overview
Market Statistics
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Size in 2024: USD 4.5 Billion
Market Forecast in 2033: USD 11.0 Billion
Market Growth Rate: 10.40%(2025-2033)
According to the latest report by IMARC Group, the South Korea orphan drugs market size reached USD 4.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.0 Billion by 2033, exhibiting a growth rate (CAGR) of 10.40% during 2025-2033.
Request PDF Sample for more detailed market insights: https://www.imarcgroup.com/south-korea-orphan-drugs-market/requestsample
South Korea Orphan Drugs Industry Trends and Drivers:
The market for orphan medications in South Korea is changing significantly due to advances in biotechnology and growing awareness of rare diseases. In order to meet unmet medical needs, pharmaceutical companies are concentrating on creating focused medicines for uncommon disorders by utilizing gene therapy and precision medicine. The need for orphan medications is rising as a result of the improved early discovery of uncommon diseases made possible by the use of sophisticated diagnostic technologies. Research institutes and biotech companies are working together to promote innovation, with an increasing focus on customized therapies based on each patient's unique genetic profile. Addressing important health issues, South Korea is positioned as a major player in the global orphan medication market thanks to its strong R&D environment and robust healthcare infrastructure.
Trends in the orphan medicine industry are being shaped by regulatory incentives that promote R&D spending. The South Korean government expedites the development of innovative treatments by providing tax breaks and expedited approvals for orphan drugs. The need for specialist therapies is also rising as a result of the growth of patient advocacy groups, who advocate for improved access to care and raise awareness. Drug discovery is changing as a result of the combination of AI and big data analytics, which makes it possible for businesses to find possible orphan drug candidates more quickly. The market for orphan pharmaceuticals is developing to provide patients with rare diseases with state-of-the-art treatments that improve their quality of life and treatment results as South Korea keeps placing a high priority on healthcare innovation.
South Korea Orphan Drugs Industry Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest South Korea Orphan Drugs Market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
The report has segmented the market into the following categories:
Drug Type Insights:
- Biological
- Non-Biological
Disease Type Insights:
- Oncology
- Hematology
- Neurology
- Cardiovascular
- Others
Phase Insights:
- Phase I
- Phase II
- Phase III
- Phase IV
Top Selling Drugs Insights:
- Revlimid
- Rituxan
- Copaxone
- Opdivo
- Keytruda
- Imbruvica
- Avonex
- Sensipar
- Soliris
- Others
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
- Others
Regional Insights:
- Seoul Capital Area
- Yeongam (Southeastern Region)
- Honam (Southwestern Region)
- Hoseo (Central Region)
- Others
Competitive Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. Additionally, the report features detailed profiles of all major companies in the South Korea Orphan Drugs industry.
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
